Published January 2015 | Version v1
Journal article

Integrity of 111In-radiolabeled superparamagnetic iron oxide nanoparticles in the mouse

  • 1. Nanomedicine Science and Technology Center, Northeastern University, Boston, MA 02115 (United States)
  • 2. Department of Pharmaceutical Sciences, Northeastern University, Boston, MA 02115 (United States)

Description

Introduction: Iron-oxide nanoparticles can act as contrast agents in magnetic resonance imaging (MRI), while radiolabeling the same platform with nuclear medicine isotopes allows imaging with positron emission tomography (PET) or single-photon emission computed tomography (SPECT), modalities that offer better quantification. For successful translation of these multifunctional imaging platforms to clinical use, it is imperative to evaluate the degree to which the association between radioactive label and iron oxide core remains intact in vivo. Methods: We prepared iron oxide nanoparticles stabilized by oleic acid and phospholipids which were further radiolabeled with 59Fe, 14C-oleic acid, and 111In. Results: Mouse biodistributions showed 111In preferentially localized in reticuloendothelial organs, liver, spleen and bone. However, there were greater levels of 59Fe than 111In in liver and spleen, but lower levels of 14C. Conclusions: While there is some degree of dissociation between the 111In labeled component of the nanoparticle and the iron oxide core, there is extensive dissociation of the oleic acid component

Availability note (English)

Available from http://dx.doi.org/10.1016/j.nucmedbio.2014.08.014

Additional details

Identifiers

DOI
10.1016/j.nucmedbio.2014.08.014;
PII
S0969-8051(14)00489-2;

Publishing Information

Journal Title
Nuclear Medicine and Biology
Journal Volume
42
Journal Issue
1
Journal Page Range
p. 65-70
ISSN
0969-8051
CODEN
NMBIEO

Optional Information

Copyright
Copyright (c) 2014 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.